Pennsylvania Trust Co raised its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 484.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 22,387 shares of the medical instruments supplier’s stock after buying an additional 18,554 shares during the period. Pennsylvania Trust Co’s holdings in Becton, Dickinson and were worth $4,368,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. ProShare Advisors LLC increased its position in shares of Becton, Dickinson and by 7.8% in the first quarter. ProShare Advisors LLC now owns 357,269 shares of the medical instruments supplier’s stock worth $65,537,000 after buying an additional 25,809 shares in the last quarter. Profund Advisors LLC increased its position in shares of Becton, Dickinson and by 14.9% in the first quarter. Profund Advisors LLC now owns 8,712 shares of the medical instruments supplier’s stock worth $1,598,000 after buying an additional 1,127 shares in the last quarter. Foster & Motley Inc. increased its position in shares of Becton, Dickinson and by 2.2% in the first quarter. Foster & Motley Inc. now owns 37,349 shares of the medical instruments supplier’s stock worth $6,851,000 after buying an additional 820 shares in the last quarter. UMB Bank N A MO increased its position in shares of Becton, Dickinson and by 604.7% in the first quarter. UMB Bank N A MO now owns 66,409 shares of the medical instruments supplier’s stock worth $12,182,000 after buying an additional 56,985 shares in the last quarter. Finally, First Manhattan Co. increased its position in shares of Becton, Dickinson and by 7.9% in the first quarter. First Manhattan Co. now owns 29,049 shares of the medical instruments supplier’s stock worth $5,220,000 after buying an additional 2,115 shares in the last quarter. 87.41% of the stock is currently owned by institutional investors and hedge funds.

Shares of Becton, Dickinson and Company (NYSE BDX) traded up 0.315% on Monday, reaching $199.195. 134,032 shares of the company’s stock traded hands. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $206.63. The firm has a market capitalization of $45.33 billion, a P/E ratio of 57.688 and a beta of 1.05. The company’s 50-day moving average is $200.05 and its 200-day moving average is $189.42.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The firm had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. During the same quarter in the previous year, the business posted $2.35 earnings per share. The business’s revenue for the quarter was down 5.1% on a year-over-year basis. Equities research analysts anticipate that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be given a $0.73 dividend. This represents a $2.92 dividend on an annualized basis and a yield of 1.47%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is presently 83.43%.

COPYRIGHT VIOLATION WARNING: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/28/pennsylvania-trust-co-increases-position-in-becton-dickinson-and-company-bdx.html.

A number of equities analysts have recently commented on the stock. Bank of America Corporation reissued a “buy” rating and issued a $225.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. BidaskClub raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Monday, August 14th. Zacks Investment Research raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price target for the company in a report on Monday, July 17th. Cowen and Company reaffirmed a “buy” rating and set a $230.00 price target on shares of Becton, Dickinson and in a report on Monday, August 14th. Finally, Barclays PLC reaffirmed an “equal weight” rating and set a $210.00 price target (up from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Becton, Dickinson and has a consensus rating of “Buy” and a consensus target price of $195.79.

In other Becton, Dickinson and news, insider Gary M. Cohen sold 15,044 shares of Becton, Dickinson and stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $200.43, for a total value of $3,015,268.92. Following the transaction, the insider now owns 95,270 shares in the company, valued at $19,094,966.10. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Nabil Shabshab sold 6,149 shares of Becton, Dickinson and stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $201.76, for a total value of $1,240,622.24. Following the completion of the transaction, the insider now owns 15,648 shares in the company, valued at approximately $3,157,140.48. The disclosure for this sale can be found here. In the last quarter, insiders sold 48,605 shares of company stock worth $9,718,986. Company insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.